GHK-Cu
Copper-binding tripeptide with human topical evidence for skin remodeling and collagen synthesis; injectable use largely unstudied.
Reviewed by Mei Li, PhD, Chief Science Officer
What GHK-Cu Is
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, an endogenous human peptide first isolated from plasma in 1973 by biochemist Loren Pickart. Pickart's original observation was that a factor present in human albumin caused aged liver tissue to synthesize proteins in a manner resembling younger tissue. The bare peptide (GHK) binds copper with high affinity, and the resulting GHK-Cu complex is the biologically active form most studied. Endogenous plasma levels are reported to decline with age, from roughly 200 ng/mL near age 20 to about 80 ng/mL by age 60, which has driven interest in it as a marker and modulator of tissue-repair capacity. It falls in the broad class of matrikines, small ECM-derived peptides that signal to cells during remodeling. Today it is most familiar as a cosmetic skincare ingredient.
Mechanism of Action
Mechanistically, GHK-Cu is described as both a copper carrier and a signaling peptide. In cell and animal models it stimulates synthesis and controlled turnover of collagen and glycosaminoglycans and modulates matrix metalloproteinases and their inhibitors, supporting extracellular-matrix remodeling. It also shows antioxidant behavior, including quenching reactive byproducts of lipid peroxidation. The most far-reaching claim, developed by Pickart and Margolina in their 2018 International Journal of Molecular Sciences review, is that GHK can up- or down-regulate a large number of human genes spanning tissue remodeling, antioxidant defense, anti-inflammatory signaling, and nerve and vascular maintenance, effectively nudging gene expression toward a healthier profile. These pathways are best characterized in vitro and in animal models.
What Published Research Has Examined
The human research base is concentrated in dermatology and cosmetics. As summarized in the 2015 BioMed Research International review, several placebo-controlled facial studies in women reported that topical GHK-Cu creams improved skin laxity, firmness, density, and fine-line depth, quantified by ultrasound and profilometry, generally over roughly 12 weeks. A one-month thigh-biopsy study (Abdulghani et al.) reported greater collagen synthesis with GHK-Cu than with vitamin C or retinoic acid comparators. Preclinical wound-healing work spans rodents, rabbits, pigs, and dogs, and reviews describe investigational interest in hair, nerve tissue, bone, intestinal lining, and blood vessels. A critical qualifier: essentially all controlled human data involve topical application to skin.
Key Findings and the Topical-vs-Injectable Gap
The clearest, most reproducible findings are topical and cosmetic: measurable improvements in skin quality metrics and biopsy-confirmed collagen synthesis. The gene-expression work is intriguing but is largely omics and mechanistic rather than clinical-outcome data, and several cosmetic trials are small or industry-linked. The most important gap for readers is route of administration. Human evidence exists for topical GHK-Cu; injectable and systemic use in humans is not well studied. The favorable topical profile cannot be assumed to transfer to injected use, where controlled human data are lacking. This distinction is central to interpreting claims made about GHK-Cu online, which often blur the well-supported topical evidence with poorly characterized injectable use.
Regulatory Status
GHK-Cu is unscheduled and research-use-only in the injectable/systemic context, while remaining a long-established, widely used topical cosmetic ingredient. It is not FDA-approved as a finished drug. Notably, it is not among the seven peptides on the FDA Pharmacy Compounding Advisory Committee (PCAC) July 23-24, 2026 docket for the 503A Bulks List; that docket consists of BPC-157, TB-500, KPV, MOTS-c, emideltide, epitalon, and semax. GHK-Cu is therefore outside the current compounding-bulks conversation entirely, and its status should not be conflated with the peptides under active PCAC review.
Safety Considerations and Related Compounds
In the published literature, topical GHK-Cu at cosmetic concentrations has a generally favorable tolerability profile, with mostly local effects such as mild irritation or occasional contact sensitivity. Because the complex delivers copper, cumulative copper exposure is the theoretical concern most often raised, though controlled topical studies have not flagged systemic copper toxicity at studied concentrations. Safety by injectable or systemic routes is not established in the literature. Related compounds studied in adjacent repair and remodeling contexts include BPC-157 and TB-500 for tissue healing, KPV for anti-inflammatory signaling, and epitalon in longevity research. This profile is educational and describes only what published research has examined; it is not medical guidance.
Key published studies
| Study | Journal | Year | Finding |
|---|---|---|---|
| GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration | BioMed Research International | 2015 | Review by Pickart and colleagues compiling collagen/GAG remodeling, antioxidant, and wound-healing actions plus placebo-controlled facial and thigh-biopsy topical data; narrative review, human evidence largely topical. |
| Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data | International Journal of Molecular Sciences | 2018 | Pickart and Margolina review of gene-expression data reporting GHK modulates a large number of human genes across remodeling, antioxidant, and anti-inflammatory pathways; mechanistic, largely in-vitro/omics evidence. |
| The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health | Oxidative Medicine and Cellular Longevity | 2012 | Review of GHK-Cu antioxidant and anti-inflammatory activity and declining endogenous levels with age; preclinical and mechanistic evidence, hypothesis-generating for cognitive and aging contexts. |
Regulatory status
Current status: Unscheduled / RUO. Unscheduled / RUO. PepSense tracks FDA filings and updates this record as the regulatory picture changes. See the FDA PCAC tracker for the July 2026 vote and what happens next.